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Here, we show that transcription factors bound to
regulatory sequences can be identified by purifying
these unique sequences directly from mammalian
cells in vivo. Using targeted chromatin purification
(TChP), a double-pull-down strategy with a tetracy-
cline-sensitive ‘‘hook’’ bound to a specific promoter,
we identify transcription factors bound to the
repressed g-globin gene-associated regulatory re-
gions. After validation of the binding, we show that,
in human primary erythroid cells, knockdown of a
number of these transcription factors induces
g-globin gene expression. Reactivation of g-globin
gene expression ameliorates the symptoms of
b-thalassemia and sickle cell disease, and these fac-
tors provide potential targets for the development of
therapeutics for treating these patients.INTRODUCTION
The sensitivity of proteomics technology has been improved dur-
ing recent years to a level where it becomes feasible to purify
very small amounts of proteins and obtain their identity by
mass spectrometry (Walther and Mann, 2010). As a result, it
has become possible to attempt the direct identification of pro-
teins bound to chromatin in vivo in mammalian cells. Attempts
to identify such proteins directly have been published before(De´jardin and Kingston, 2009; Fujita and Fujii, 2011; Wang
et al., 2013). De´jardin and Kingston used an elegant hybridization
technique called proteomics of isolated chromatin (PICh) to
identify factors bound to telomeres. Because there are two telo-
meres per chromosome and hence almost 100 telomeres per
mouse or human cell, their total length approximates 0.01%–
0.07% of the genome (De´jardin and Kingston, 2009). Fujita and
Fujii applied insertional chromatin immunoprecipitation (iChIP)
to directly identify components of b-globin chicken HS4 insulator
complexes using an exogenous locus containing 24 copies of a
chicken HS4-core plasmid possessing 16 copies of LexA bind-
ing sequences in a hematopoietic cell line (Fujita and Fujii,
2011). Wang et al. used chromatin-interacting protein MS
(ChIP-MS) to identify MSL complex interactions and identified
MSL-enriched histone modifications associated with the active
genes (Wang et al., 2013). We are interested in identifying chro-
matin-bound proteins to promoter sequences and regulatory
regions of a particular gene. Such DNA elements are normally
present in two copies per genome, each constitute less than
1 kb, and, therefore, are almost two orders of magnitude less
abundant than the combined telomeres, multicopy exogenous
plasmid locus, and active gene bodies mentioned above. It is
unlikely that such a small percentage of the genome can be
purified sufficiently by PICh, iChIP, or ChIP-MS to allow the iden-
tification of specific proteins. We therefore devised a different
method, using the human b-globin locus as a proof of principle
in this report.
Our specific interest in this locus originates from the suppres-
sion of the human fetal g-globin genes in adults, because a
release of this suppression is of clinical interest for patientsCell Reports 4, 589–600, August 15, 2013 ª2013 The Authors 589
suffering from b-thalassemia or sickle cell disease. Presently, the
most common treatments for these diseases are blood transfu-
sions combined with iron chelation therapy, or treatment with
hydroxyurea or short chain fatty acids, the latter two leading to
an increase of fetal g-globin gene expression (Bank, 2006;
Coleman and Inusa, 2007; Mankidy et al., 2006; Perrine, 2008;
Stamatoyannopoulos, 2005). The g-globin chains replace the
absent or abnormal b-globin chains, thus ameliorating disease
symptoms. However, these treatments are not satisfactory
because they do not lead to a normal quality of life nor do they
prevent a relatively early death. At present, bone marrow trans-
plantation is the only effective cure, a risky procedure that is
not available to the large majority of patients.
Despite intense research efforts bymany laboratories, it is only
partly understood how the human g-globin genes are normally
suppressed around the time of birth when expression switches
to the adult b-globin gene. Several factors have been identified
to be involved in the suppression of the g-globin genes. For
example, BCL11A and KLF1 were recently shown to lead to
elevated g-globin gene expression when their activity is sup-
pressed (Borg et al., 2011; Sankaran et al., 2008; Xu et al.,
2010, 2011). Interestingly, the promoters of the g-globin genes
were previously identified as the regions responsible for their
suppression (Berry et al., 1992; Dillon and Grosveld, 1991; Li
et al., 2001; Starck et al., 1994; Yu et al., 2006), whereas the
BCL11A protein binds to a region downstream of the g-globin
genes. BCL11A interacts with SOX6, GATA1, FOG1, and the
NuRD repressor complex, and these interactions are thought
to act via the g-globin gene promoter and regulatory regions
(Sankaran et al., 2008; Xu et al., 2010). KLF1 is indirectly involved
as it positively regulates the b-globin and BCL11A promoters.
This suggests that the g-globin promoter interacts with the sur-
rounding regulatory sequences to achieve silencing.
The direct proteomics approach that we developed, targeted
chromatin purification (TChP), entails the pull-down of a protein
hook that is crosslinked to the g-globin gene promoter. Impor-
tantly, this will also purify interacting cis-regulatory regions
because these are spatially organized in a chromatin hub (Palstra
et al., 2003; Patrinos et al., 2004). Here, we show that this
approach successfully identified a number of protein factors
bound to the globin chromatin hub whose reduced expression
leads to the activation of the g-globin genes in human erythroid
cells. These factors shed light on the mechanism of g-globin
gene switching and may provide targets for the development
of drugs that release the suppression of g-globin genes in b-thal-
assemia and sickle cell disease patients.
RESULTS
Experimental Design
All experiments were carried out following the Dutch guidelines
of the METC (Medical-Ethical Committee) and the DEC (Ethics
Committee Animal Experiments). We opted for an unbiased pro-
teomics approach by introducing Tet operator (TetO) sequences
in the upstream g-globin promoter. These sequences are bound
by a tagged TetR protein that is used as a hook to pull down
the g-globin promoter together with its associated regulatory
sequences by affinity purification. We considered that the exper-590 Cell Reports 4, 589–600, August 15, 2013 ª2013 The Authorsimental system should meet three important requirements. First,
the bait should not disturb the normal expression pattern of the
g-globin gene. Second, the fragments of interest each constitute
less than one-millionth of the genome; hence, many cells are
needed to enable the purification of sufficient amounts of mate-
rial for further analysis. Third, a large number of general (contam-
inating) chromatin-binding proteins will be found, because the
relevant sequences constitute such a small part of the genome.
The control sample should therefore be a close mimic of the
experimental sample to control for these contaminants.
We used mouse transgenesis to generate a model system
meeting these requirements. The basic design of the approach
is schematically shown in Figure 1. Binding sites for the bacterial
tetracycline repressor protein (TetR) were inserted into a human
b-globin minilocus that contains the locus control region (LCR),
the Ag-globin gene, and the 30 hypersensitive site 1 (Figure 1A).
Previous experiments have shown that such a g-globinminilocus
is regulated properly in the mouse (Dillon and Grosveld, 1991).
The g-globin gene is expressed in the embryo and early mouse
fetal liver; it is silenced around embryonic day 14 (E14) in the fetal
liver and remains silenced in the adult (Peterson et al., 1998;
Strouboulis et al., 1992).
The modified globin minilocus (LCR-TetO-g) was introduced
into transgenic mice that are p53 null (LCR-TetO-g::p53-null
mice) to facilitate the derivation of immortalized cell lines (Dolznig
et al., 2001; Donehower et al., 1992; von Lindern et al., 2001).
Next, we constructed a triple tag in the TetR protein (TetR3T,
Figure 1A) that enables sequential purification on HA and
streptavidin affinity beads. The TetR3T cDNA was cloned in
the hematopoietic expression vector pIE3.9IntpolyAA (Ohneda
et al., 2002), and this construct (TetR3T) was introduced in
transgenic mice expressing the E. coli BirA biotin ligase from
the pEV expression vector (de Boer et al., 2003); BirA efficiently
biotinylates the Bio tag of the TetR3T protein as shown by prob-
ing western blots of crude nuclear extracts with HRP-streptavi-
din (see below). Crossing of the TetR3T::BirA mice with the
LCR-TetO-g::p53-null mice resulted in quadruple LCR-TetO-
g::TetR3T::BirA::p53-null mice after several breeding and
selection steps. Quadruple LCR-TetO-g::TetR3T::BirA::p53-null
embryos were collected at 13.5 days postcoitum (dpc), a devel-
opmental time point coinciding with the suppression of the
human g-globin transgene, and used to generate fetal-liver
derived erythroid progenitor cell lines (Dolznig et al., 2001; Peter-
son et al., 1998; Strouboulis et al., 1992; von Lindern et al., 2001)
(Figure 1B). One of these cell lines was used for the suppressed
Ag-globin chromatin hub purification and identification of the
bound proteins by mass spectrometry (Figures 1C and 1D).
Development of the Experimental System
First, the TetO site was tested in electrophoretic mobility shift
assays with TetR3T::BirA fetal liver cell extracts. This showed
strong binding of TetR3T to the TetO sequence (data not shown).
We found no evidence for binding of other proteins. Next, seven
copies of the TetO sequence were introduced into the StuI site
380 bp upstream of the transcription initiation site of the g-globin
gene in the g-globin minilocus (Figure 1A). This LCR-TetO-g
locus was used for transgenesis, and several LCR-TetO-g trans-
genic lines were selected for further analysis (Figure S1). The
Figure 1. Scheme of the TChP Approach
(A) Generation of the LCR-TetO-g and TetR3T-G1HRD constructs resulting in the two transgenic mouse lines: TetR3T::BirA and LCR-TetO-g::p53-null mice.
(B) LCR-TetO-g::TetR3T::BirA::p53-null mice were used to derive the LCR-TetO-g::TetR3T::BirA::p53-null cell line.
(C) Purification of the g-globin chromatin hub after formaldehyde crosslinking, the LCR-TetO-g::TetR3T::BirA::p53-null cell-line chromatin is fragmented and
used for HA and biotin pull-down. Small red dashes represent hypothetical crosslinks.
(D) Decrosslinking of the isolated chromatin proteins, identification by mass spectrometry, and functional testing for potential role in g-globin regulation.developmental mRNA expression pattern of g-globin from the
LCR-TetO-g locus was analyzed, and the results obtained with
line 05-23736-05, which contains two copies of the transgene,
are shown in Figure 2A. From these data, we conclude that the
LCR-TetO-g locus is expressed properly during development.
It is active during the embryonic period, suppressed during the
late fetal liver stage, and remains inactive in the adult.
We next performed circularized chromosome conformation
capture sequencing (4C-Seq) to visualize the spatial organiza-
tion of the suppressed human LCR-TetO-g-globin minilocus in
the mouse fetal-liver-derived cell line. This showed that the sup-
pressed human g-globin gene promoter is indeed in close prox-
imity to human LCR 50HS2, 3, 4, and 30HS1 (Figure 2B).In parallel, the TetR3T cDNA was cloned in the
pIE3.9IntpolyAA vector (Ohneda et al., 2002) resulting in the
TetR3T construct. This vector recapitulates the hematopoietic
expression pattern of the mouse Gata1 gene, driving expression
at all developmental stages of erythroid cells, also when the
g-globin gene is suppressed. The TetR3T protein is composed
of the TetR DNA binding domain coupled to CFP, three copies
of a nuclear localization signal, an HA tag, and a biotinylation
tag (Figures 1A and 2C).
Purification of the Suppressed g-Globin Chromatin Hub
Erythroid progenitor cell lines (von Lindern et al., 2001) were
derived from LCR-TetO-g::TetR3T::BirA::p53null fetal livers atCell Reports 4, 589–600, August 15, 2013 ª2013 The Authors 591
Figure 2. Transgenic Mouse Proof of Principle Experiments
(A) S1 nuclease protection analysis of globin expression in LCR-TetO-g transgenic mice. RNA was prepared from fetal livers and adult blood of transgenic mice
carrying two copies of the LCR-TetO-g transgene (line 05-23736-05). Controls are shown on the right. E12.5 WT: RNA from liver of wild-type mouse E12.5 mouse
embryo; E12.5 PAC8.1: RNA from liver of E12.5 mouse embryo carrying a complete human b-globin locus. The positions of the protected fragments for mouse
a-globin (m-a), b-major globin (m-bm), and human g-globin (h-g) are indicated. Size marker: pUC18 cut with MspI.
(B) LCR-TetO-g-globin chromatin hub. Analysis of the LCR-TetO-g-globinmini locus spatial organization inmouse erythroid fetal liver cell line by 4C-seq using the
g-globin promoter as the viewpoint (indicated by the eye symbol). Bars indicate interactions of restriction fragments with the viewpoint as measured by the
number of normalized sequence reads. The human b-globin minilocus LCR-TetO-g cosmid fragments are indicated on the bottom; ^ indicates the junction
between two fragments.
(C) Construction and expression of the TetR3T hook protein. Top panel: depiction of the TetR3T cDNA construction in the G1HRD erythroid-specific expression
vector (Ohneda et al., 2002). Bottom panel left: nuclear localization of TetR3T in E13.5 TetR3T transgenicmouse fetal liver cells. Top picture shows phase contrast
picture of a group of cells. Bottom picture shows nuclear CFP fluorescence in the same cells. Middle and left panel: TetR3T expression as shown by streptavidin-
HRP-stained western blot of fetal liver and brain extracts of WT, TetR3T, BirA, and TetR3T::BirA compound transgenic E13.5 embryos.
Molecular weights are shown on the right. See also Figure S1.E13.5. The cell lines were cloned and further propagated in vitro.
Out of these, a cell line was randomly selected that showed
the expression pattern of mouse fetal liver at this stage of
development; very low expression of the human g-globin gene
and high levels of mouse a- and b-globin expression (Figure 2A).
This cell line was expanded for the subsequent optimization of
each step of the biochemical purification of the suppressed
g-globin associated chromatin. First, the TetR3T precipitation
by streptavidin beadswas tested (Figure 3A).We also used chro-592 Cell Reports 4, 589–600, August 15, 2013 ª2013 The Authorsmatin immunoprecipitation (ChIP) to confirm that the TetO
repeats were bound by the TetR3T protein, and released upon
the addition of doxycycline (Figure 3B). The TetR3T protein
and its bound TetO sequences could be efficiently pulled down
by anti-HA beads as well as streptavidin (Figure 3), in principle,
enabling consecutive pull-downs.
We next tested whether the chromatin captured with the HA
beads could be eluted efficiently by the addition of HA peptide,
allowing a subsequent pull-down step on the eluted chromatin
Figure 3. Affinity Purification of the g-Globin Chromatin Hub
(A) Left panel; gel electrophoresis of the nuclear extracts after colloidal blue staining. The first lane contains a control extract from an identical cell line not
containing the TetR3T construct. Middle panel; detection of the TetR3T protein with an HA-specific antibody onwestern blot. Right panel: detection of the TetR3T
protein with streptavidin HRP on western blot. *Naturally occurring biotinylated proteins (de Boer et al., 2003).
(B) Top:map of the g-globin locus (not to scale) and the distances of the various fragments from the TetO sites in the promoter. Bottom: chromatin precipitation of
the different fragments on streptavidin beads in the presence or absence of doxycycline. Themouse b-major and Amylase genes were used as negative controls.
(C) Left panel: gel electrophoresis of the nuclear extracts after ChIP with an HA-specific antibody. The lanes show the bound, washed, and eluted fractions of the
beads. H and L are the heavy and light chains of the HA-specific antibody. Right panel: western blot detection of the TetR3T protein with streptavidin HRP of the
lanes shown in the left panel. *Naturally occurring biotinylated proteins (de Boer et al., 2003).
(D) Top: same as top in (B). Bottom: PCR detection of the various fragments of the g-globin locus or the mouse b-major and amylase control genes after ChIP by
binding to HA beads followed by HA peptide elution, in the presence or absence of doxycycline. Bars in (B) and (D) represent averages of three independent
measurements; error bars represent SD.
See also Tables S1 and S2.by streptavidin. The results show that all of the bound material
could be eluted efficiently by HA peptide (Figures 3C and 3D).
Both pull-downs showed an enrichment of the sequences up-
stream and downstream of the TetO sites (Figures 3B and 3D).
Subsequently all parameters for TChP were optimized (Table
S1). This included fixation conditions, crosslinking, choice of
beads for pull-down, buffer composition, blocking agents to pre-
vent nonspecific binding, large-scale culture, and the elution
conditions. The optimization details are shown in the Extended
Experimental Procedures.
The optimization resulted in conditions that gave over 50-fold
purification for both the HA- and the biotin pull-down (Figure 3).
In the final optimized protocol the yield of the purification steps,measured as TetO DNA recovery after the HA and biotin pull-
downs, was estimated at <2% of the starting material.
Proteomics Analysis of the Pulled-Down Chromatin
Currently, the sensitivity limit for peptide identification by LC-MS
(Orbitrap) mass spectrometry is in the high attomole range. This
suggests that a minimum number of 3 3 109 cells is required to
recover sufficient amounts of suppressed g-globin chromatin
complexes with the optimized procedure. This would still be on
the borderline of detection. The maximum culture volume we
were able to handle, using the optimized purification protocol,
was 1.2 l. We therefore repeated the purification several times
to maximize identification of possible specific hits. To purifyCell Reports 4, 589–600, August 15, 2013 ª2013 The Authors 593
Table 1. Summary of the Selected Proteins and Their Identified Peptides
Identified
Protein Score Da Coverage (%) Uniq Pept. Total Pept. Description gil
1 Ybx1 275 35,822 22.4 3 3 Y box protein 1 gij55451
2 Apex1 258 35,867 14.2 3 3 Apurinic/apyrimidinic endonuclease 1 gij6753086
3 Cdc5l 232 92,361 4.6 2 2 Cell division cycle 5-like (S. pombe) gij22779899
4 Gtf2f2 205 28,421 20.1 4 4 General transcription factor IIF, polypeptide 2 gij39930425
5 Mybbp1a 156 152,773 1.9 2 2 MYB binding protein (P160) 1a gij2645205
6 Gata1 142 43,274 9 2 2 GATA binding protein 1 gij6679947
7 Nap1l1 130 45,602 6.9 2 2 Nucleosome assembly protein 1-like 1 gij7657357
8 Ctnnbl1 93 65,421 3.2 2 2 Catenin, beta-like 1 gij18460918
9 Supt5h 79 120,988 4.5 3 3 Suppressor of Ty 5 homolog gij22094123
10 Chd4 77 94,191 3.4 2 2 Chromodomain helicase DNA binding protein 4 gij13543768
11 Sox30 62 84,285 2.9 2 7 SRY-box containing gene 30 gij27734194
12 Dbf4 56 75,042 4.2 2 3 DBF4 homolog (S. cerevisiae) gij7304903
13 Zfp148 56 86,469 3.8 2 11 Zinc finger protein 148 gij1724124
14 Tcfeb 55 59,616 3.4 2 8 Transcription factor EB gij4454797
See also Table S3.chromatin hub, complexes 1.2 l of cells were grown to a density
of 2.53 106 cells per ml. For each experiment, we grew two cul-
tures in parallel, one with and one without doxycycline. The cells
were harvested and treated with 1% formaldehyde, and the
crosslinked chromatin was subjected to the isolation procedure.
After the final step, the chromatin was decrosslinked, and the
proteins were separated by SDS-PAGE. The lanes were sliced,
and each slice was used for mass spectrometry analysis. We
performed a total of four independent experiments, collectively
identifying 441 proteins with a Mascot score of R55 and R2
unique identified peptides. Of these, 427 were present in the
doxycycline-treated purification experiments including ubiqui-
tous nuclear proteins such as histones and splicing factors
(350), had low-quality peptide fragmentation spectra, or were
very unlikely to be involved in the suppressed g-globin chromatin
hub (77), such as abundant structural and cytoplasmic proteins,
glutathione S-transferase, and ribosomal proteins. These were
relegated to the bottom of the list, leaving 14 candidates (Tables
1 and S3). Among these 14 candidates were a number of factors
that have been reported previously to bind to the LCR or the
g-globin promoter: APEX1, GATA1, CDC5l, ZFP148 (ZBP-89),
TCFEB, and CHD4 (Mi-2b) (Hirayama and Shinozaki, 1996;
Harju-Baker et al., 2008; Karmakar et al., 2010; Mahajan et al.,
2005; Olave et al., 2007; Reece-Hoyes et al., 2011; Woo et al.,
2011).
Chromatin Hub Occupancy of Identified Proteins
To validate the chromatin occupancy of the identified proteins,
we selected a set of proteins known to bind to the locus, and a
number of proteins not known to bind to the locus for which
we could obtain antibodies for ChIP experiments. ChIP experi-
ments were carried out on the b-globin LCR and g-globin locus
in human primary erythroid progenitors (Figure 4) as well as the
mouse fetal-liver-derived cell line (Figure S2). We tested a
selected number of identified protein factors for binding (Table 1),
namely, APEX1, GATA1, NAP1L1, SUPT5h, CDC5l, ZFP148594 Cell Reports 4, 589–600, August 15, 2013 ª2013 The Authors(ZBP-89), CHD4 (Mi2-b), CTNNBL1, TCFEB, and YBX1. Six out
of these ten proteins, APEX1, GATA1, CDC5l, ZFP148 (ZBP-
89), NAP1L1, and TCFEB, showed binding to different elements
within the locus. In particular, the 50HS3 and 50HS4 regulatory re-
gions showed binding of at least five proteins, whereas the other
elements showed binding of only one or two of these proteins
(Figure 4). Particularly striking was the strong enrichment of
ZBP-89 (Zfp148 in mouse) at 50HS2 (Figure 4). The ChIP experi-
ments in mouse cells carrying the LCR-TetO-g-globin minilocus
transgene resulted in a very similar recruitment profile of these
factors.We also tested some of the protein factors that were pre-
sent in doxycycline-treated pull-downs as negative controls,
these included, EHMT1, FANCI, SON, and HMGB3. However,
none these showed recruitment to the locus (Figure S2). These
results suggest that the experiments identified a number of fac-
tors that are bound to the globin locus, which might be involved
in g-globin transcription regulation.
Functional Assessment of Identified Proteins
We next carried out functional assays for a number of the pro-
teins identified, to address whether they have any effect on the
expression of the suppressed g-globin genes. We tested this
with the human homologs of these proteins in human erythroid
progenitor (HEP) cells (Borg et al., 2010; Leberbauer et al., 2005).
ZBP-89 knockdown (65% at the protein level) resulted in a
2.5-fold rise in g-globin mRNA expression and a rise in HbF (Fig-
ures 5A–5C; Table 2). This was accompanied by an increase of
the percentage of cells expressing high HbF levels as deter-
mined by immunohistochemistry (IHC) (Figure 5D; Table 2).
These results were reproduced with HEP cells derived from six
different healthy individuals (data not shown).
Similar sets of experiments were performed for CDC5L,
APEX1, TFEB, CTNNBL1, and SUPT5H. We also included the
HMGB3 protein that was present in doxycycline-treated pull-
down control experiments. In all cases, at least two of the small
hairpin RNA (shRNA) tested resulted in a knockdown of the
Figure 4. Chromatin Occupancy of Selected Set of Protein Factors Identified by TChP along the b-Globin Locus in Human Erythroid
Progenitor Cells
Results are shown only for proteins with more than 1.8-fold enrichment. The enrichments are normalized relative to antibody immunoglobulin (Ig) G species and
negative region 1 kb downstream of Ag-globin gene. Bars represent averages of two experiments. The different transcription factors tested are color-coded in the
bar graph as shown on the right. See also Figure S2 and Tables S2 and S3.factor, and the experiments were reproduced in at least two in-
dependent donors. The results of these knockdown experiments
are summarized in Table 2. Knockdown of the CDC5L and
APEX1, TFEB proteins in HEP cells resulted in increased level
of g-globin mRNA and HbF, which was also observed at the
cellular level by immunohistochemistry (Table 2). Two of the
nonbinding proteins in our ChIP experiments (Table 2; Figure 4),
SUPT5H and CTNNBL1 as well as the HMGB3 control protein,
were also knocked down efficiently by different shRNAs, but
these knockdowns showed no or very little change in the level
of g-globin at mRNA or protein level. We conclude from these
knockdown experiments that a number of the factors we identi-
fied by TChP indeed appear to be involved in suppression of
g-globin gene expression. Importantly, knockdowns of some
of the factors had no effect strongly suggesting that the
observed induction of g-globin gene expression upon knock-
down of ZBP-98, CDC5L, APEX1, and TFEB is specific.
DISCUSSION
Here, we show that chromatin factors bound to unique
sequences can be identified directly through the purification of
the target locus sequences (TChP) in vivo. Although the results
obtained are not directly comparable with those of De´jardin
and Kingston (2009), the TChP approach presented here may
be more generally applicable and suitable to the isolation of
unique sequences. The two approaches are fundamentally
different, and each method has its advantages and disadvan-
tages. The PICh method involves a hybridization step to capture
the target chromatin, whereas TChP relies on the binding of theTetR protein to the TetO sequences. The latter is likely to bemore
efficient than hybridization but has the disadvantage that it re-
quires the introduction of sequences that serve as a ‘‘bait’’ into
the naturally occurring sequences. Therefore, a control should
be carried out to ensure that the introduction of the bait has
not changed the behavior of the target sequence. The advantage
is that, once the sequences have been introduced, multiple
purification steps can be carried out with the same bait, using
the appropriate tags and elution conditions. In each approach,
it is essential to run a comparable negative control to allow
the identification of candidate binding proteins. Dejardin and
Kingston list approximately 200 proteins in the control PICh
pull-down, probably due to mismatched hybridization and
nonspecific sticking of irrelevant chromatin. The latter is sup-
ported by the observation that more than one-third of the PICh
background proteins were also found among the TChP back-
ground proteins.
Using TChP, we identified 14 unique protein IDs and selected
a number of these candidates for further functional analysis by
analysis of their recruitment to the human b-globin locus and
the effect of their reduced protein level on g-globin expression
in adult human HEP cells.
ZBP-89 (also known as BFCOL1, BERF-1, ZNF148 in human
and Zfp148 in mouse) knockdown resulted in g-globin gene acti-
vation. ZBP-89 is a Kru¨ppel-type zinc finger transcription factor
that binds to a GC-rich region, and subsequently represses or
activates its target genes. ZBP-89 interacts with GATA1 and
MAFK, and it is involved in erythroid development and differen-
tiation (Brand et al., 2004; Woo et al., 2008, 2011). We recently
showed that the 5FMC complex is recruited to ZBP-89 targetCell Reports 4, 589–600, August 15, 2013 ª2013 The Authors 595
Figure 5. Lentiviral shRNA-Mediated Knockdown of ZBP-89
(A) Top panel: immunoblot for ZBP-89 shRNA-mediated knockdown in HEP cells. First lane: no virus control. NT, nontarget shRNA lentiviral transducedHEP cells.
Bottom panel: APEX1 staining serving as loading control.
(B) S1 nuclease protection analysis of globin expression in ZBP-89 depleted HEP cells. First lane: no virus control, NT; nontarget shRNA, ZBP-89 sh2, 3, and 5;
short hairpins to human ZBP-89. Controls (to the right): 3 3 HEP; triple amount of RNA from non-virus-treated HEP and FL (human fetal liver) as the positive
control; size marker: pUC18xMspI. The positions of human a-, g-, and b-globin protected fragments are indicated.
(C) HPLC hemoglobin analysis of the ZBP-89 shRNA knockdown in HEP cells.
(D) HbF Immunohistochemistry of ZBP-89 shRNA knockdown HEP cells. Scale bars, 10 mm.
See also Table S3.genes, and together they are involved in transcriptional regula-
tion (Fanis et al., 2012).
CDC5l (cell division cycle 5-like) is a cell-cycle regulator impor-
tant for G2 to M transition and has sequence-specific DNA bind-596 Cell Reports 4, 589–600, August 15, 2013 ª2013 The Authorsing activity (CTCAGCG). Its DNA binding domain has similarities
to MYB, which is known to be involved in g-globin repression
(Jiang et al., 2006; Kuroyanagi et al., 2006). Cdc5l is able to
bind to the g-globin promoter (Olave et al., 2007), and it interacts
Table 2. Summary of Functional Studies
Knockdown
Efficiency
Globin mRNA
g/(g+b) HbF % (HPLC) HbF-Positive Cells % (IHC) Binds to (ChIP)
Scramble 0% 0.2 4.0 5
ZBP-89 65% 0.5 9.0 18 HS3 and HS2
CDC5L 90% 0.7 12.8 25 HS4, HS3, g-globin gene, and 3HS1
APEX1 55% 0.8 19.0 19 HS3 and gamma gene
TCFEB 65% 0.6 Not determined Not determined HS4 and HS3
HMGB3 60% 0.1 Not determined Not determined No binding detected
CTNNBL1 85% 0.2 6.1 Not determined No binding detected
SUPT5 70% 0.2 5.3 Not determined No binding detected
The experiments were performed in HEP cells grown from at least two independent donors. The knockdown experiments are expressed as average of
at least two different shRNA viruses. See also Table S3.with b-catenin-like 1 protein (CTNNBL1) (Conticello et al., 2008).
Interestingly, CDC5L knockdown increased fetal hemoglobin,
whereas a reduced level of CTNNBL1 had no substantial effect
on g-globin expression (Table 2).
Moderate knockdown of APEX1 (Apurinic-apyrimidinic endo-
nuclease 1) also increased g-globin expression. Apex1 is amulti-
functional protein involved in DNA repair activity, proofreading
exonuclease activity, and modulating DNA binding activity of
several transcription factors including AP-1, CREB, and NRF2.
Interestingly, AP-1 and CREB bind to the human b-globin LCR
50HS2 (Johnson et al., 2002; Talbot and Grosveld, 1991).
APEX1 belongs to a multiprotein complex necessary for both
transcription and DNA replication at the b-globin locus (Karma-
kar et al., 2010).
TFEB was recently identified as a transcription factor that
binds to human b-globin regulatory elements in a high-
throughput regulatory network mapping yeast one-hybrid assay
(Reece-Hoyes et al., 2011). Reduced level of TFEB also resulted
in more than 2-fold increase in g-globin expression.
HMGB3, CTNNBL1, and SUPT5H protein knockdown did not
result in g-globin gene activation. In addition, we failed to show
any binding of these proteins to the human b-globin regulatory
regions, suggesting that these factors are not involved in
g-globin repression.
In the knockdown experiments, we observed g-globin upre-
gulation for four out of six identified factors tested. Moreover,
identifying specific proteins such as GATA1, CHD4, CDC5l
that are already known to interact with the g-globin promoter
or b-globin locus LCR provides confidence regarding the
validity of the TChP procedure developed in this paper and
suggests that this method could be used more generally. Using
the p53-null mouse background, it could be applied to any
other (immortalized) cell type that could either be grown in large
amounts in culture or be isolated directly, e.g., from liver or
brain.
The TChP method may be improved further in order to in-
crease the yield and decrease the background contamination
by incorporating some extra steps, other crosslinking agents,
and/or tags. The next generation of the TChP can be more effi-
cient and generally applicable by designing zinc finger proteins.
This makes TChP much easier as no artificial sequences (tetO)
would have to be introduced and endogenous loci could betargeted directly. Moreover, this could be carried out in the
appropriate cell lines rather than using mice. In addition, the
multiple tag used for sequential pull-downs could be further
improved, for instance, by including other affinity tags such as
V5, MYC, or FLAG that are not dependent on BirA and known
to work well upon formaldehyde crosslinking will further reduce
the complexity of TChP (Kolodziej et al., 2009). In addition, a den-
sity fractionation step to isolate the chromatin after crosslinking
could be used to remove contaminating proteins. Probably the
most important loss of efficiency is the crosslinking of the TetR
protein to the TetO sequence. TetR binds as a dimer to an in-
verted repeat sequence (Orth et al., 2000), and its crosslinking
may be improved substantially by the incorporation of additional
lysine or cysteine amino acids next to the binding sequence, and
the incorporation of dG next to the TetO binding site. It is known
that lysine-dG and cysteine-dG are the most efficient combina-
tions for formaldehyde crosslinking (Lu et al., 2010; Orth et al.,
2000). Further improvements may be achieved by adding a re-
striction site to the bait that would cleave the target DNA
sequence from the TetO sequences. In addition, a sequence-
specific protease site could be introduced between the tag
and DNA binding moiety of the TetR3T protein such as TEV,
which recognizes a linear protein sequence (Kapust et al.,
2002), or SUMOstar protease (Lifesensors), which recognizes a
3D SUMO structure (Malakhov et al., 2004). These adjustments
significantly reduce the complexity of TChP and make it adopt-
able for other laboratories that would be likely to identify in vivo
chromatin-bound proteins.
In summary, we have shown that proteins bound to unique
sequences in the genome can be purified sufficiently for identifi-
cation by mass spectrometry. This resulted in the identification
of a number of known but also proteins that are potentially
involved in the suppression of the human g-globin genes.
EXPERIMENTAL PROCEDURES
DNA Constructs
A human g-globin gene ClaI-KpnI fragment from the g-globin minilocus (Dillon
and Grosveld, 1991) was modified as a subclone by insertion of the TetO
heptamer (Gossen and Bujard, 1992) ligated to a short random sequence con-
taining SwaI and PmeI restriction enzyme digestion sites into the StuI site of
the g-globin gene promoter 380 bp upstream of the transcription initiation
site and a loxP sequence inserted in the ClaI site (sequences are provided inCell Reports 4, 589–600, August 15, 2013 ª2013 The Authors 597
the Extended Experimental Procedures) (Figures 1 and S1). The modified ClaI-
KpnI fragment was cloned back into the minilocus by standard l phage pack-
aging (Stratagene) and transduction into E. coli DH10B. DNA was isolated and
the integrity of the modified minilocus established by cleavage with EcoRI and
gel electrophoresis (Figure S1).
The 642 bp TetR binding domain (Gossen and Bujard, 1992) was cloned in-
frame with CFP cDNA (pECFP-N1, Clontech). The insert was recloned into
pEYFP-Nuc replacing eYFP (Clontech) thereby gaining the 33 NLS and
SV40 polyA sequence. A biotinylation tag (de Boer et al., 2003) and HA tag
(YPYDVPDYA), separated by a few glycine residues as linker and restriction
sites, were cloned in-frame from ligated overlapping oligonucleotides between
the NLS and poly A resulting in TetR3T cDNA. The sequences of overlapping
oligonucleotides for HA-Bio tag synthesis are provided in the Extended Exper-
imental Procedures.
The TetR3T fragment was excised by EcoRI-NotI digestion and inserted into
the NotI site of the G1HRD expression vector (Ohneda et al., 2002). The result-
ing TetR3T-RG1HRD vector was tested for integrity and standard transfection
and expression in MEL cells, which demonstrated its localization to the
nucleus by CFP fluorescence.
Transgenesis and Cell-Line Derivation
The minilocus DNA was cut with SalI, the insert fragment isolated by gel elec-
trophoresis and injected into fertilized oocytes (Dillon and Grosveld, 1991). A
number of gminilocus transgenic mice was obtained, one of which contained
two copies of the minilocus (line 05-23736-05). Its integrity was established by
EcoRI digestion and Southern blots of genomic DNA (Figure S1). Similarly The
Asp718-PvuI TetR3T restriction fragment was isolated from the vector by gel
electrophoresis and injected into fertilized eggs (de Boer et al., 2003). The
resulting mice expressed the TetR3T protein in the erythroid lineage. Finally,
the mouse strains were crossed to yield LCR-TetO-g::TetR3T::BirA::p53-null
mice (Donehower et al., 1992). These mice were intercrossed and E13.5 fetal
liver cells were cultured to obtain the LCR-TetO-g::TetR3T::BirA::p53-null cell
line (Dolznig et al., 2001).
Cell Cultures
The culturing of human erythroid proerythroblasts (HEPs) (Leberbauer et al.,
2005) and LCR-TetO-g::TetR3T::BirA::p53-null cells (von Lindern et al., 2001)
was essentially as published with minor modifications provided in the
Extended Experimental Procedures.
Chromatin Immunoprecipitation and g-Globin Chromatin
Purification with Targeted Chromatin Purification
Crosslinked chromatin was prepared by adding formaldehyde directly to cul-
ture medium to a final concentration of 1% and incubated for 10 min at room
temperature. The reaction was stopped by the addition of 1 M glycine to a final
concentration 0.125 M. The cells were disrupted, and the DNA was frag-
mented by sonication at 0C. g-Globin locus, DNA sequences, and their bound
proteins were precipitated using HA-agarose beads. The precipitated material
was eluted by HA peptides followed by a sequential Dynabeads M-280 strep-
tavidin (Invitrogen) pull-down for further purification. The efficiency of purifica-
tion was analyzed by immunoprecipitation and quantitative PCR. Purified
material was analyzed by mass spectrometry for identification of proteins
bound to the g-globin locus and its associated DNA sequences. The anti-
HA-agarose beads pull-down, HA elution, further purification by streptavidin
pull-down, ChIP, and the analysis of precipitated material by immunoprecipi-
tation and quantitative PCR protocols are detailed in the Extended Experi-
mental Procedures.
Mass Spectrometry
One-dimensional SDS-PAGE gel lanes were cut into 2 mm slices using an
automatic gel slicer and subjected to in-gel reduction with dithiothreitol,
alkylation with iodoacetamide, and digestion with trypsin (Promega,
sequencing grade), essentially as described (Wilm et al., 1996) Nanoflow
LC-MS/MS was performed on an 1100 series capillary LC system (Agilent
Technologies) coupled to either an LTQ-Orbitrap mass spectrometer
(Thermo Scientific) or an LTQ linear ion trap (Thermo Scientific), both oper-
ating in positive mode and equipped with a nanospray source. Peptide598 Cell Reports 4, 589–600, August 15, 2013 ª2013 The Authorsmixtures were trapped on a ReproSil C18 reversed phase column
(Dr. Maisch GmbH; column dimensions 1.5 cm 3 100 mm, packed in-
house) at a flow rate of 8 ml min1. Peptide separation was performed
on ReproSil C18 reversed phase column (Dr Maisch GmbH; column
dimensions 15 cm 3 50 mm, packed in-house) using a linear gradient
from 0% to 80% B (A = 0.1% formic acid; B = 80% [v/v] acetonitrile,
0.1% formic acid) in 70 min and at a constant flow rate of 200 nl min1
using a splitter. The column eluent was directly sprayed into the ESI
source of the mass spectrometer. Mass spectra were acquired in contin-
uum mode; fragmentation of the peptides was performed in data-depen-
dent mode. Peak lists were automatically created from raw data files using
the Mascot Distiller software (version 2.3; MatrixScience). The Mascot
search algorithm (version 2.2, MatrixScience) was used for searching
against the NCBI database (taxonomy: Mus musculus; release
NCBInr_20081130.fasta). The peptide tolerance was set to 10 ppm
(Orbitrap) or to 2 Da (ion trap) and the fragment ion tolerance was set
to 0.8 Da. A maximum number of two missed cleavages by trypsin were
allowed, and carbamidomethylated cysteine and oxidized methionine
were set as fixed and variable modifications, respectively. As would be
expected, the protein hits in TChP are quite weak. Using the statistical
procedures that are commonly used (typically a false discovery rate
[FDR] of 1% for the protein database search algorithm), the hits would
not be indicated as valid hits. The FDRs applied to this data set were
therefore loosened up. The Mascot score cutoff value for a positive protein
hit was set to 55 with more than two unique peptides. Selection of hits to
follow up was based on gene ontology analysis (gene ontology terms used
‘‘transcription factor’’, ‘‘chromatin remodeling factors’’).Circularized Chromosome Conformation Capture Sequencing
4C material was prepared essentially as described (Palstra et al., 2003; Soler
et al., 2010). ApoI was used as the primary restriction endonuclease. Purified
4C DNA was used for 4C-Seq library preparation as described (Palstra et al.,
2003; Soler et al., 2010; Stadhouders et al., 2011), using NlaIII as secondary
restriction endonuclease. Viewpoint-interacting DNA fragments were PCR-
amplified using viewpoint-specific divergent primers (forward-specific for Ag
50-CAG GTA GTT GTT CCC CTT CA; reverse 50- AAT CCA TTT CGG CAA
AGA ATT C) linked to standard Illumina adaptor sequences. The resulting 4C
library was single-read sequenced on the Illumina Genome Analyzer II platform
generating 76 bp reads. Images were recorded and analyzed by the GAP
pipeline. The resulting reads were trimmed to remove viewpoint-specific
primer sequences andmapped against NCBI build hg18 of the human genome
using ELAND alignment software. To calculate the coverage, aligned reads
were extended to 56 bp in the 30 direction using the 4C-Seq pipeline (Thong-
juea et al., 2013). The interaction-enriched regions per ApoI fragment were
measured by calculating the number of reads per million (RPM) per restriction
fragment. Data were visualized using a local mirror of the UCSC genome
browser.Lentiviral shRNA-Mediated Knockdown
shRNA vectors were obtained from the TRC Mission human and mouse
library from Sigma. Packaging was done as described by the Sigma Mission
library protocol. HEP cells were transduced with lentiviruses containing
shRNAs, puromycin was added at a concentration of 1 mg ml1 for 24 hr,
and the cells were kept in culture for another 5 days before harvesting and
further analysis.RNA Purification
Total RNA was extracted from cells using the TRI reagent (Sigma) and used
directly for S1 nuclease protection analysis of globin expression.S1 Nuclease Protection Assays
S1 nuclease protection assays were performed as described (Hanscombe
et al., 1991). The dried gels were exposed to a Typhoon TRIO phosphorimager
screen (GE Healthcare), and signal intensities of individual bands were quan-
tified with Image Quant 5.2.
Western Blotting
Cells (2003 105) were lysed in 100 ml of RIPA buffer (10 mM Tris-HCl [pH 7.5],
150 mMNaCl, 1%Nonidet P-40, 1%NaDOC, 0.1% SDS), the same volume of
Laemmli buffer was added and the samples were boiled for 5 min. Twenty
microliters of each sample was resolved by 4%–12% gradient SDS-PAGE
(Invitrogen) and transferred to 0.45 mm nitrocellulose membrane. The mem-
branes were blocked for 1 hr in 1 3 TBS with 2% BSA and 0.05% Tween 20
and incubated in primary (overnight) and secondary (1 hr) antibody. Primary
antibodies: Abcam FANCI (KIA1794) ab15344, ZBP-89 ab69933, CTNNBL1
ab76243, CDC5L ab51320, NAP1l1 ab21630, EHMT1 ab41969, SUPT5 sc-
101158, BAF53 ab3882, Santa Cruz APEX1 (Ref-1 C4)X sc-17774 X, CHD4
(Mi2b) sc-8774, GATA1 sc-265, SPT5 (Supt5) sc-101158, and Bethyl MCM5
A300-195A. Western blots were developed with the ECL Western Blotting
Detection Reagents (GE Healthcare) and quantified with a Kodak Image
Station 440CF.
HPLC Analysis
Hemoglobin subtypes were measured by HPLC (Bio-Rad).
Immunohistochemistry
Cells were spotted on poly-prep slides (Sigma), fixed with 4% paraformal-
dehyde, permeabilized in 10 mM citric acid (pH 6.0), and blocked with
5% BSA. Primary antibody incubation was performed in blocking solution
for 16 hr at 4C, followed by peroxidase staining. Pictures were taken
with an Olympus BX40 microscope (403 objective, NA 0.65) equipped
with an Olympus DP50 CCD camera and Viewfinder Lite 1.0 acquisition soft-
ware. HbF-positive cells were determined using Photoshop at a tolerance
level of 80.
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